Our goal for the written word is two-fold: to keep you informed about the latest news and research in Breast AI while also keeping you up to date about what’s happening within our company. Here are our top performing stories from the year:
5. AI-based screening is cost-effective at scale in breast cancer screening programmes
Results from a study published in European Radiology suggest that Transpara could unlock staggering cost savings as well as clinical outcomes within European screening programmes: €59,320 in savings and 10.8 quality adjusted life years, both per 1000 women screened.
4. Can AI act as a second reader in breast cancer screening programmes?
A recent Dutch study adds to a growing body of literature attesting to a simple fact: radiologists working together with artificial intelligence are more efficient and more effective than the traditional double reader model. ScreenPoint Medical’s CEO Pieter Kroese explores key takeaways from the research.
3. ScreenPoint Medical acquires Biomediq to expand risk assessment capabilities
ScreenPoint Medical started 2025 with a bang, acquiring Biomediq and its automatic, computer-based analysis of 2D and 3D mammograms for analysis of future risk of breast cancer. This acquisition also brought prominent researcher Andreas D. Lauritzen, PhD, to the ScreenPoint team to accelerate the development of Transpara’s risk capabilities.
2. New outcomes from the MASAI randomized controlled trial in Sweden
Published in The Lancet Digital Health, the Mammography Screening with Artificial Intelligence (MASAI) trial, conducted within the Swedish national screening program, demonstrates that Transpara-assisted workflow increased cancer detection by 29% and resulted in a 44% reduction in the screen-reading workload for radiologists. This is the first randomized controlled trial in Breast AI and Transpara remains the only breast cancer detection AI solution validated by an RCT.
And finally, our #1 story of the year:
1.Transpara® selected for $16M PRISM randomized controlled trial in USA
MASAI’s groundbreaking results cemented Transpara as the most talked-about Breast AI solution worldwide. Now, a pioneering randomized controlled trial, comprising over 400,000 mammograms and involving some of the most recognizable healthcare organizations in the United States, seeks to better understand the impact of Breast AI in the USA’s distinct screening environment. The study starts in force in early 2026.